Table 3.
Multivariate Analysis Predictors of Bevacizumab Receipt by Patient/Oncologist Characteristics*
| Characteristic | Stage IV (n = 435)† |
|
|---|---|---|
| OR | 95% CI | |
| Patient | ||
| Total patients | ||
| No. | 310 | |
| % | 71.3 | |
| Age at diagnosis, years | ||
| 65-69 | Referent | |
| 70-74 | 0.78 | 0.41 to 1.51 |
| 75-79 | 0.60 | 0.32 to 1.14 |
| 80-84 | 0.47 | 0.22 to 1.01 |
| ≥ 85 | 0.35 | 0.12 to 1.02 |
| Sex | ||
| Male | Referent | |
| Female | 1.56 | 0.95 to 2.56 |
| Race | ||
| White | Referent | |
| Black | 0.71 | 0.29 to 1.70 |
| Hispanic | 0.66 | 0.14 to 3.12 |
| Other | 0.69 | 0.26 to 1.84 |
| Marital status | ||
| Married | Referent | |
| Single/divorced | 1.04 | 0.63 to 1.72 |
| Unknown | 2.44 | 0.36 to 16.73 |
| Urban/rural location | ||
| Urban | 0.75 | 0.34 to 1.66 |
| SES, quintile | ||
| Lowest | Referent | |
| Second | 1.98 | 0.78 to 5.05 |
| Third | 1.23 | 0.50 to 3.01 |
| Fourth | 1.24 | 0.48 to 3.26 |
| Highest | 2.30 | 0.86 to 6.18 |
| Clinical | ||
| Grade | ||
| Well differentiated | Referent | |
| Moderately differentiated | 1.61 | 0.52 to 4.98 |
| Poorly differentiated | 1.19 | 0.37 to 3.85 |
| Undifferentiated | 0.37 | 0.05 to 2.51 |
| Unknown | 1.92 | 0.52 to 7.14 |
| No. of comorbidities | ||
| 0 | Referent | |
| 1 | 0.43 | 0.26 to 0.71 |
| ≥ 2 | 0.71 | 0.32 to 1.59 |
| Hypertension | ||
| No | Referent | |
| Yes | 0.89 | 0.55 to 1.46 |
| Oncologist | ||
| Sex | ||
| Male | Referent | |
| Female | 0.53 | 0.32 to 0.88 |
| US trained | ||
| No | Referent | |
| Yes | 1.08 | 0.65 to 1.78 |
| Date of graduation | ||
| < 1975 | Referent | |
| ≥ 1975 | 1.77 | 0.84 to 3.72 |
| Type of practice | ||
| Nonprivate | Referent | |
| Private | 0.96 | 0.59 to 1.55 |
| No. of patients in cohort | ||
| 1 | Referent | |
| ≥ 2 | 1.61 | 1.02 to 2.54 |
Abbreviations: OR, odds ratio; SEER, Surveillance, Epidemiology, and End Results; SES, socioeconomic status.
*
Patients > 65 years of age diagnosed with histologically confirmed colon cancer in the SEER-Medicare database who saw an oncologist between September 1, 2004, and December 31, 2005; for patients with stage IV disease, between January 1, 2005 and December 31, 2005.